A New Solution For
VASCULAR DISEASE
End Stage Renal Disease (ESRD) Is A Large Problem in the US
Approximately 100,000 people begin dialysis each year – a treatment that costs approximately $90,000 per year per patient to treat
In 2016, treating patients with ESRD cost about $35 Billion
More than 661,000 Americans have kidney failure – kidney diseases are the ninth leading cause of death in the US
Nania, R., Medicare Extends Special Services to People With Kidney Failure, AARP, October, 2019
End Stage Renal Disease (ESRD) Is A Large Problem in the US
Approximately 100,000 people begin dialysis each year – a treatment that costs approximately $90,000 per year per patient to treat
In 2016, treating patients with ESRD cost about $35 Billion
More than 661,000 Americans have kidney failure – kidney diseases are the ninth leading cause of death in the US
Nania, R., Medicare Extends Special Services to People With Kidney Failure, AARP, October, 2019
Arterial Fistulas and Grafts
Over Two Million patients globally use hemodialysis to treat ESRD.1 The Hemodialysis procedure is where the blood is filtered out through a hemodialysis machine and then returns it to the body when the kidneys are unable to function.
Hemodialysis is the most common method of renal replacement therapy and most often secured through creating an arteriovenous (AV) access site. However, these AV access sites typically have high failure rates due to stenosis. Physicians are always looking for effective and durable treatment options of AV stenosis. PTA is the most common procedure to gain vascular access in an AV stenosis. Patency rates can be as low as 23% at 6 months in AVG’s.2 FLEX Vessel Prep™ System offers a unique approach to opening stenosis with less trauma and potentially longer lasting patency.
References:
- U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014.
-
Kitrou, P.M., Karnabatidis, D., Endovascular Treatment of Dysfunctional Vascular Access: From Fundamentals to an Algorithmic Approach, Endovascular Today Supplement, Fall 2019
Over Two Million patients globally use hemodialysis to treat ESRD.1 The Hemodialysis procedure is where the blood is filtered out through a hemodialysis machine and then returns it to the body when the kidneys are unable to function.
Hemodialysis is the most common method of renal replacement therapy and most often secured through creating an arteriovenous (AV) access site. However, these AV access sites typically have high failure rates due to stenosis. Physicians are always looking for effective and durable treatment options of AV stenosis. PTA is the most common procedure to gain vascular access in an AV stenosis. Patency rates can be as low as 23% at 6 months in AVG’s.2 FLEX Vessel Prep™ System offers a unique approach to opening stenosis with less trauma and potentially longer lasting patency.
References:
- U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014.
-
Kitrou, P.M., Karnabatidis, D., Endovascular Treatment of Dysfunctional Vascular Access: From Fundamentals to an Algorithmic Approach, Endovascular Today Supplement, Fall 2019
VentureMed Group, Inc. develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of PAD and stenoses of AV fistulas and grafts.
VentureMed Group, Inc. is a member of Medical Alley
VentureMed Group, Inc. develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of PAD and stenoses of AV fistulas and grafts.
VentureMed Group, Inc. is a member of Medical Alley